Sep 12, 2023 · The MT-302 Phase 1 study (NCT05969041) is an open-label dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and ...
The study has 4 Cohorts. Each Cohort has 4 Cycles. For Cohorts 1-3, the dosing regimen will be every 14 days for 3 doses, followed by administration once ...
Prerequisite: CFA MT301. Special Topics in Music Theory; this course covers a variety of approaches, styles, and periods. Individual subjects are offered on ...
Sep 13, 2023 · MT-302 is the Company's lead development candidate for in vivo immune cell programming and delivers TROP2-targeting RNA chimeric antigen ...